Synergistic Antimicrobial Systems

The invention integrates bacteriocin-based entities with distinct technologies such as AI, IoT, blockchain, and new materials to create more powerful and targeted antimicrobial systems.

The original patent provides methods and compositions for reducing microbial growth, including infections, using bacteriocins. However, these methods may not be effective against all types of bacteria, and the lack of integration with other technologies limits their potential. The new inventive concept addresses these limitations by combining bacteriocin-based entities with AI-driven diagnostic modules, blockchain-secured genomic data, IoT-enabled monitoring devices, and novel antimicrobial materials to create more effective and personalized antimicrobial systems.

The synergistic antimicrobial system comprises a bacteriocin-based entity that selectively targets Gram-negative bacteria, integrated with an AI-driven diagnostic module for real-time bacterial identification and susceptibility testing. This allows for personalized antimicrobial treatment, where a patient-specific profile is generated using blockchain-secured genomic data, and a bacteriocin-based therapeutic composition is tailored to the patient's specific microbiome. The system may also include an IoT-enabled monitoring device for real-time tracking of treatment efficacy and resistance development. Additionally, novel antimicrobial materials can be created by embedding bacteriocin-based entities in nanofibrous matrices, integrated with sensor modules for real-time detection of bacterial growth and antimicrobial resistance. A smart antimicrobial delivery system can also be developed, comprising a bacteriocin-based entity encapsulated in a microcapsule, integrated with a machine learning algorithm for optimized release and targeting of antimicrobial agents.

The new claims introduce novel and non-obvious combinations of bacteriocin-based entities with distinct technologies, providing a synergistic effect that enhances the effectiveness and personalization of antimicrobial systems. The integration of AI, IoT, blockchain, and new materials with bacteriocin-based entities is a new and innovative approach that overcomes the limitations of the original patent.

Alternative embodiments of the inventive concept may include the use of different AI algorithms, IoT devices, or blockchain platforms. Variations may also include the development of new antimicrobial materials, such as bacteriocin-coated nanoparticles or bacteriocin-infused hydrogels.

The synergistic antimicrobial systems have significant commercial potential in the healthcare industry, particularly in the treatment of antibiotic-resistant infections. The market for antimicrobial systems is growing rapidly, driven by the increasing need for effective treatments against antibiotic-resistant bacteria. The inventive concept's potential applications include hospitals, clinics, and pharmaceutical companies.